The key list

Powered by

Leading companies in China by R&D expenditure

This month our pharma industry key list brings you the 15 largest companies in China by R&D expenditure, as ranked by GlobalData's Pharma Intelligence Centre. All numbers as of September 2020.


Company name

R&D expenditure ($million)

Headquarters locationNumber of employees

Jiangsu Hengrui Medicine Co Ltd

382China24,700

CSPC Pharmaceutical Group Ltd

202China17,300

Innovent Biologics Inc

185China1,445

Shanghai Fosun Pharmaceutical (Group) Co Ltd

152China31,370

Zai Lab Ltd

120China298

Sichuan Kelun Pharmaceutical Co Ltd

105China19,990

Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd

84China23,131

Joincare Pharmaceutical Group Industry Co Ltd

78China12,699

Tasly Pharmaceutical Group Co Ltd

75China9,235

Huadong Medicine Co Ltd

68China-

Zhejiang Hisun Pharmaceutical Co Ltd

65China8,072

Humanwell Healthcare Group Co Ltd

59China15,137

Shenzhen Salubris Pharmaceuticals Co Ltd

58China4,622

Zhejiang Huahai Pharmaceutical Co Ltd

52China6,050

Luye Pharma Group Ltd

43China4,417

Share this article

Go to article: Home | Under the microscopeGo to article: In this issueGo to article: SHL Medical Company InsightGo to article: SHL MedicalGo to article: ContentsGo to article: MimotopesGo to article: NewsGo to article: VEGA AustraliaGo to article: Covid-19 executive briefing by GlobalDataGo to article: WipotecGo to article: Nasal spray vaccine for Covid-19Go to article: Datwyler Company Insight Go to article: DatwylerGo to article: Covid-19 clinical trials continue to rise in BrazilGo to article: BiogazelleGo to article: AstraZeneca’s Phase I / II Covid-19 vaccine trial Go to article: SwiftpakGo to article: MTPA resumes screening and enrolment for global Phase III clinical trial of MT-1Go to article: Biesterfeld Go to article: The pharma industry briefingGo to article: From antitoxins to Covid-19 drugs: charting the history of antibody drugsGo to article: Quality control: pharma manufacturing inspections explainedGo to article: Molnár-Institute Company InsightGo to article: Molnar-InstituteGo to article: Oxytocin: the therapeutic potential of the ‘love hormone’Go to article: AI-enabled risk detection in pharma manufacturingGo to article: Dr. Paul LohmannGo to article: Addressing the long-term effects of Covid-19Go to article: Eyes on the prize: the latest in retinitis pigmentosa gene therapiesGo to article: HOF Sonderanlagenbau Company Insight Go to article: HOF SonderanlagenbauGo to article: Breaking the taboo: disrupting the fertility sectorGo to article: Neutralising the gluten threat: are we on the cusp of a coeliac disease breakthrough? Go to article: Nolato Company Insight Go to article: NolatoGo to article: Pharmacovigilance case intake: why the hesitation to automate?Go to article: Deals in brief powered by GlobalDataGo to article: The key list powered by GlobalDataGo to article: Zenatek Go to article: Global markets and indices powered by GlobalDataGo to article: Macro-economic indicators (1 of 2) powered by GlobalDataGo to article: Macro-economic indicators (2 of 2) powered by GlobalDataGo to article: EventsGo to article: Next issue